Morgan Stanley analyst Michael Ulz raised the firm’s price target on Kyverna Therapeutics (KYTX) to $25 from $20 and keeps an Overweight rating on the shares. Topline data from the registrational Phase 2 study of KYV-101 in stiff person syndrome are expected in early 2026, notes the analyst, who cites “increasing conviction in the potential of KYV-101” for the firm’s higher target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
- Kyverna Therapeutics: Promising Clinical Progress and Strategic Execution Support Buy Rating
- Kyverna Therapeutics: Strategic Advancements and Financial Stability Underpin Buy Rating
- Kyverna Therapeutics Reports Increased Losses Amid R&D Focus
- Kyverna Therapeutics reports Q3 EPS (85c), consensus (95c)